N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Project Purple has awarded a $375,000 Research Recovery Grant to researchers at the University of Texas MD Anderson Cancer Center to continue critical pancreatic cancer research.

June 26, 2026

Vol.52 No.25

Clinical Roundup

TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows

Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer.

June 26, 2026

Vol.52 No.25

Clinical Roundup

Sylvester researchers discover method of disrupting inflammatory network that helps pancreatic cancer resist treatment

Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven inflammatory network that helps pancreatic cancer resist treatment, according to a study led by researchers at Sylvester Comprehensive Cancer Center.

June 26, 2026

Vol.52 No.25

Drugs & Targets

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

The European Commission granted Marketing Authorization for Padcev (enfortumab vedotin), in combination with Keytruda (pembrolizumab), as neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy in the European Union.

June 26, 2026

Vol.52 No.25

Podcast

Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science

The oncology community is still riding the high of the success of daraxonrasib—the first drug to show real promise in treating metastatic pancreatic cancer. The drug doubled overall survival for patients in the phase III RASolute-302 trial.

June 10, 2026

N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer

YOU MAY BE INTERESTED IN

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows

Sylvester researchers discover method of disrupting inflammatory network that helps pancreatic cancer resist treatment

EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer

Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science

Renew today!

Subscriber content

Never miss an issue!

Login